In vivo and in vitro degradation of peptide YY3–36 to inactive peptide YY3–34 in humans
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Peptide YY (PYY) is a 36-amino-acid peptide released from enteroendocrine cells upon food intake. The NH 2 terminally truncated metabolite, PYY 3–36, exerts anorexic effects and has received considerable attention as a possible antiobesity drug target. The kinetics and degradation products of PYY metabolism are not well described. A related peptide, neuropeptide Y, may be degraded from the COOH terminus, and in vivo studies in pigs revealed significant COOH-terminal degradation of PYY. We therefore investigated PYY metabolism in vitro after incubation in human blood and plasma and in vivo after infusion of PYY 1–36 and PYY 3–36 in eight young, healthy men. A metabolite, corresponding to PYY 3–34, was formed after incubation in plasma and blood and during the infusion of PYY. PYY 3–34 exhibited no agonistic or antagonistic effects on the Y2 receptor. PYY 1–36 infused with and without coadministration of sitagliptin was eliminated with half-lives of 10.1 ± 0.5 and 9.4 ± 0.8 min (means ± SE) and metabolic clearance rates of 15.7 ± 1.5 and 14.1 ± 1.1 ml·kg−1·min−1 after infusion, whereas PYY 3–36 was eliminated with a significantly longer half-life of 14.9 ± 1.3 min and a metabolic clearance rate of 9.4 ± 0.6 ml·kg−1·min−1. We conclude that, upon intravenous infusion in healthy men, PYY is inactivated by cleavage of the two COOH-terminal amino acids. In healthy men, PYY 3–36 has a longer half-life than PYY 1–36.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604 · cited 1×
“Anorexigenic effects of PYY3–36 have been demonstrated in several studies with intravenous administration of PYY3–36 (6, 16, 32, 34), whereas infusions of PYY1–36 have no effect on food intake (34), suggesting that the cleavage of PYY1–36 to PYY3–36 is not as complete and rapid as for GLP-1 (34).”
BackgroundKieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 5×
“Anorexigenic effects of PYY3–36 have been demonstrated in several studies with intravenous administration of PYY3–36 (6, 16, 32, 34), whereas infusions of PYY1–36 have no effect on food intake (34), suggesting that the cleavage of PYY1–36 to PYY3–36 is not as complete and rapid as for GLP-1 (34).”
BackgroundSelf-citationVilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444
Self-citationPeptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity
Boey, D., Lin, S., Karl, T., Baldock, P., Lee, N., Enriquez, R., Couzens, M., Slack, K., Dallmann, R., Sainsbury, A., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0237-0 · Cited by 186
Cited by
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Svane, M. S., Jørgensen, N. B., Bojsen-Møller, K. N., Dirksen, C., Nielsen, S., Kristiansen, V. B., Toräng, S., Wewer Albrechtsen, N. J., Rehfeld, J. F., Hartmann, B., et al. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.121 · Cited by 185
Self-citationNielsen, M. S., Ritz, C., Wewer Albrechtsen, N. J., Holst, J. J., le Roux, C. W., & Sjödin, A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa061 · Cited by 65
Self-citationEstablished and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2021) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000612 · Cited by 42
Metadata
- Authors
- Toräng, S., Bojsen-Møller, K. N., Svane, M. S., Hartmann, B., Rosenkilde, M. M., Madsbad, S., & Holst, J. J.
- Venue
- American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Publisher
- American Physiological Society
- Published
- 2016-05-01
- Volume
- 310
- Issue
- 9
- Pages
- R866-R874
- ISSN
- 0363-6119 (ISSN-L)
- 1522-1490
- OpenAlex
- W2341428856
- Cited by
- 61
- References
- 6
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In vivo and in vitro degradation of peptide YY3–36 to inactive peptide YY3–34 in humans. https://app.cochat.ai/papers/10.1152/ajpregu.00394.2015
- The paper
- Toräng, S., Bojsen-Møller, K. N., Svane, M. S., Hartmann, B., Rosenkilde, M. M., Madsbad, S., & Holst, J. J. (2016). In vivo and in vitro degradation of peptide YY3–36 to inactive peptide YY3–34 in humans. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. https://doi.org/10.1152/ajpregu.00394.2015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.